Overview

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The underlying goal of this study is to assess [123I]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Institute for Neurodegenerative Disorders
Treatments:
Adenosine